305 related articles for article (PubMed ID: 37197536)
1. A comprehensive clinical evaluation of first-line drugs for ALK-positive advanced non-small cell lung cancer.
Wang WQ; Xu T; Zhang JJ; Wang Y; Wang Y; Zhang W; Zhu JG
J Thorac Dis; 2023 Apr; 15(4):1935-1947. PubMed ID: 37197536
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China.
Luo X; Zhou Z; Zeng X; Peng L; Liu Q
Front Public Health; 2022; 10():985834. PubMed ID: 36211665
[TBL] [Abstract][Full Text] [Related]
3. Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in Sweden.
Naik J; Beavers N; Nilsson FOL; Iadeluca L; Lowry C
Appl Health Econ Health Policy; 2023 Jul; 21(4):661-672. PubMed ID: 37173513
[TBL] [Abstract][Full Text] [Related]
4. ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib.
Kim ES; Barlesi F; Mok T; Ahn MJ; Shen J; Zhang P; Ou SI
Future Oncol; 2021 May; 17(14):1709-1719. PubMed ID: 33569983
[TBL] [Abstract][Full Text] [Related]
5. Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis.
Zhao M; Shao T; Shao H; Zhou C; Tang W
BMC Cancer; 2024 Feb; 24(1):186. PubMed ID: 38331773
[TBL] [Abstract][Full Text] [Related]
6. Chinese perspectives on clinical efficacy and safety of alectinib in patients with
Yu H; Sun S; Hu X; Xia J; Wang J; Chen H
Onco Targets Ther; 2019; 12():6481-6495. PubMed ID: 31616158
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of first-line treatments for patients with advanced anaplastic lymphoma kinase mutated, non-small cell cancer: A systematic review and network meta-analysis.
Peng Y; Zhao Q; Liao Z; Ma Y; Ma D
Cancer; 2023 Apr; 129(8):1261-1275. PubMed ID: 36748799
[TBL] [Abstract][Full Text] [Related]
8. Alectinib versus crizotinib in ALK-positive advanced non-small cell lung cancer and comparison of next-generation TKIs after crizotinib failure: Real-world evidence.
Wang Y; Shen S; Hu P; Geng D; Zheng R; Li X
Cancer Med; 2022 Dec; 11(23):4491-4500. PubMed ID: 35616090
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness Analysis of 6 Tyrosine Kinase Inhibitors as First-Line Treatment for ALK-Positive NSCLC in China.
Zhang M; Zheng B; Yang W; Jiang H; Sun X; Zhao Z; Li G; Dong H
Clin Med Insights Oncol; 2024; 18():11795549241257234. PubMed ID: 38827520
[TBL] [Abstract][Full Text] [Related]
10. Comparison of lorlatinib, alectinib and brigatinib in ALK inhibitor-naive/untreated ALK-positive advanced non-small-cell lung cancer: a systematic review and network meta-analysis.
Wang L; Sheng Z; Zhang J; Song J; Teng L; Liu L; Li Q; Wang B; Li B
J Chemother; 2022 Apr; 34(2):87-96. PubMed ID: 34139965
[TBL] [Abstract][Full Text] [Related]
11. Comparative safety of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced anaplastic lymphoma kinase-mutated non-small cell lung cancer: Systematic review and network meta-analysis.
Luo Y; Zhang Z; Guo X; Tang X; Li S; Gong G; Gao S; Zhang Y; Lin S
Lung Cancer; 2023 Oct; 184():107319. PubMed ID: 37597303
[TBL] [Abstract][Full Text] [Related]
12. Canadian perspectives: update on inhibition of
Melosky B; Cheema P; Agulnik J; Albadine R; Bebb DG; Blais N; Burkes R; Butts C; Card PB; Chan AMY; Hirsh V; Ionescu DN; Juergens R; Morzycki W; Poonja Z; Sangha R; Tehfe M; Tsao MS; Vincent M; Xu Z; Liu G
Curr Oncol; 2018 Oct; 25(5):317-328. PubMed ID: 30464681
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of First-Line Treatment Strategies for Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis.
Peng L; Lu D; Xia Y; Hong S; Selvaggi G; Stebbing J; Sun Y; Liang F
Front Oncol; 2021; 11():754768. PubMed ID: 34820326
[TBL] [Abstract][Full Text] [Related]
14. A Bayesian network meta-analysis of ALK inhibitor treatments in patients with ALK-positive non-small cell lung cancer.
Zheng B; Jiang H; Yang W; Li Y; Liang B; Zhu J; Chen N; Chen M; Zhang M
Cancer Med; 2023 Aug; 12(15):15983-15997. PubMed ID: 37334877
[TBL] [Abstract][Full Text] [Related]
15. Expert consensus of management of adverse drug reactions with anaplastic lymphoma kinase tyrosine kinase inhibitors.
Zhou F; Yang Y; Zhang L; Cheng Y; Han B; Lu Y; Wang C; Wang Z; Yang N; Fan Y; Wang L; Ma Z; Zhang L; Yao Y; Zhao J; Dong X; Zhu B; Zhou C
ESMO Open; 2023 Jun; 8(3):101560. PubMed ID: 37230029
[TBL] [Abstract][Full Text] [Related]
16. Alectinib for treating patients with metastatic
Samacá-Samacá D; Prieto-Pinto L; Peréz AY; Valderrama C; Hernández F
Lung Cancer Manag; 2023 Jun; 12(2):LMT59. PubMed ID: 37287941
[TBL] [Abstract][Full Text] [Related]
17. Update on Lorlatinib: Role in Reducing the Risk of Disease Progression in ALK-Positive NSCLC.
Yun KM; Bazhenova LA
Cancer Manag Res; 2022; 14():843-850. PubMed ID: 35250311
[TBL] [Abstract][Full Text] [Related]
18. A patient with ALK-positive lung adenocarcinoma who survived alectinib-refractory postoperative recurrence for 4 years by switching to ceritinib.
Matsumura Y; Inomata S; Yamaguchi H; Mine H; Takagi H; Watanabe M; Ozaki Y; Yamaura T; Fukuhara M; Muto S; Okabe N; Hasegawa T; Shio Y; Suzuki H
Thorac Cancer; 2021 Aug; 12(15):2225-2228. PubMed ID: 34159737
[TBL] [Abstract][Full Text] [Related]
19. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
Goto Y; Yamamoto N; Masters ET; Kikkawa H; Mardekian J; Wiltshire R; Togo K; Ohe Y
Adv Ther; 2020 Jul; 37(7):3311-3323. PubMed ID: 32472430
[TBL] [Abstract][Full Text] [Related]
20. Comparing efficacy and safety of upfront treatment strategies for anaplastic lymphoma kinase-positive non-small cell lung cancer: a network meta-analysis.
Filetti M; Lombardi P; Falcone R; Giusti R; Giannarelli D; Carcagnì A; Altamura V; Scambia G; Daniele G
Explor Target Antitumor Ther; 2023; 4(6):1136-1144. PubMed ID: 38213541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
